

Iván Henríquez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8508101/publications.pdf>

Version: 2024-02-01

22
papers

766
citations

623188

14
h-index

676716

22
g-index

22
all docs

22
docs citations

22
times ranked

983
citing authors

#	ARTICLE	IF	CITATIONS
1	Symptom prevalence in the last week of life. <i>Journal of Pain and Symptom Management</i> , 1997, 14, 328-331.	0.6	158
2	Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 167-172.	0.4	152
3	Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. <i>Neuro-Oncology</i> , 2013, 15, 797-805.	0.6	77
4	Exeresis and Brachytherapy as Salvage Treatment for Local Recurrence After Conservative Treatment for Breast Cancer: Results of a Ten-Year Pilot Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 804-810.	0.4	66
5	Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. <i>Radiation Oncology</i> , 2014, 9, 102.	1.2	49
6	Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment. <i>Brachytherapy</i> , 2015, 14, 859-865.	0.2	41
7	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. <i>Journal of Neuro-Oncology</i> , 2016, 127, 569-579.	1.4	40
8	Cosmetic outcome of breast conservative treatment for early stage breast cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 334-338.	1.2	29
9	Intraoperative and external beam radiotherapy in advanced resectable gastric cancer: Technical description and preliminary results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 17, 183-189.	0.4	24
10	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Biomedicines</i> , 2021, 9, 1247.	1.4	22
11	Clinical Applications of Molecular Biomarkers in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1550.	1.7	21
12	Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal. <i>Radiation Oncology</i> , 2014, 9, 260.	1.2	19
13	Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy. <i>Radiotherapy and Oncology</i> , 2019, 141, 156-163.	0.3	19
14	Postoperative radical radiotherapy with concurrent weekly intra-arterial cis-platinum for treatment of malignant glioma: a pilot study. <i>Radiotherapy and Oncology</i> , 1989, 14, 83-88.	0.3	16
15	Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). <i>Clinical and Translational Oncology</i> , 2020, 22, 1378-1389.	1.2	11
16	Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes. <i>Clinical and Translational Oncology</i> , 2019, 21, 1044-1051.	1.2	6
17	Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. <i>Clinical and Translational Oncology</i> , 2019, 21, 420-432.	1.2	6
18	Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 251-257.	0.3	3

#	ARTICLE	IF	CITATIONS
19	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. <i>World Journal of Clinical Oncology</i> , 2021, 12, 6-12.	0.9	3
20	The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort. <i>Clinical and Translational Oncology</i> , 2016, 18, 1026-1033.	1.2	2
21	Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 792-800.	1.0	1
22	Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUC. <i>Clinical and Translational Oncology</i> , 2018, 20, 392-401.	1.2	1